<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 16pt"><B>UNITED
STATES</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 16pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 12pt; text-transform: none"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 12pt"><B>CURRENT
REPORT</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Pursuant
to Section 13 or 15(d) of the </B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Securities
Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">Date of Report
(Date of earliest event reported): <B>March 30, 2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 20pt"><B>COGENTIX
MEDICAL, INC.</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-20970</B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>13-3430173</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Identification
No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5420 Feltl Road</B>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Minnetonka, Minnesota</B></P></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>55343</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>(952) 426-6140</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">(Registrant&#8217;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vision-Sciences, Inc.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>40 Ramland Road South</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Orangeburg, New York 10962</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>Item 2.01.&#9;Completion of Acquisition
or Disposition of Assets.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 21, 2014,
Vision-Sciences, Inc., a Delaware corporation (&#8220;<U>Vision</U>&#8221; or the &#8220;<U>Company</U>&#8221;), and Visor Merger
Sub LLC, a Delaware limited liability company and of which the sole member is Vision (&#8220;<U>Merger Sub</U>&#8221;), entered
into an Agreement and Plan of Merger (the &#8220;<U>Merger Agreement</U>&#8221;) with Uroplasty, Inc., a Minnesota corporation
(&#8220;<U>Uroplasty</U>&#8221;), providing for the merger of Uroplasty with and into Merger Sub, with Merger Sub surviving as
a wholly owned subsidiary of Vision (the &#8220;<U>Merger</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 30, 2015,
Vision held a Special Meeting of Shareholders (the &#8220;<U>Special Meeting</U>&#8221;) at its corporate headquarters located
in Orangeburg, New York. At the Special Meeting, holders of a majority of the Vision shares entitled to vote at the meeting approved,
among other things, the adoption of the Merger Agreement and the issuance of shares of common stock, $0.01 par value, of Vision
(&#8220;<U>Vision Shares</U>&#8221;), in connection with the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger
Agreement, on March 31, 2015, Uroplasty merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation
under the name &#8220;Uroplasty, LLC&#8221;. Vision changed its name to &#8220;Cogentix Medical, Inc.&#8221; and the Vision Shares
will now trade on the Nasdaq Stock Market (&#8220;<U>NASDAQ</U>&#8221;) under the new symbol &#8220;CGNT&#8221;. Following the
completion of the Merger, Uroplasty&#8217;s common stock, par value $0.01 per share (&#8220;<U>Uroplasty Shares</U>&#8221;), ceased
trading on NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger
Agreement and as of the effective time of the Merger (the &#8220;<U>Merger Effective Time</U>&#8221;), each Uroplasty Share outstanding
immediately prior to the Merger Effective Time (other than Uroplasty Shares held by Uroplasty as treasury stock and Uroplasty
Shares owned by Uroplasty, Vision or any of their respective subsidiaries, which Uroplasty Shares were cancelled) was converted
into the right to receive 0.72662 Vision Shares. This calculation reflected the 3.6331 Exchange Ratio as defined in the Merger
Agreement as adjusted for Vision&#8217;s one-for-five reverse stock split plus cash (without interest) in lieu of fractional shares,
if any, in an amount equal to the product of (a) such fractional part of a Vision Share, multiplied by (b) $1.85, the closing price
for a Vision Share as reported on NASDAQ on March 30, 2015, the trading day immediately prior to the Merger Effective Time, adjusted for Vision&#8217;s one-for-five reverse stock split (collectively,
the &#8220;<U>Merger Consideration</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately following
the Merger Effective Time, Vision shareholders owned approximately 37.5% and Uroplasty shareholders owned approximately 62.5% of
the combined company on a fully-diluted basis, excluding shares of Vision common stock issuable upon the conversion of promissory
notes and warrants held by Mr. Lewis C. Pell, former Chairman of Vision (which were amended in connection with the Merger).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the Merger Effective
Time, all outstanding options to purchase Uroplasty Shares and other equity awards based on Uroplasty Shares, which were outstanding
immediately prior to the Merger Effective Time, became, respectively, options to purchase Vision Shares and, with respect to all
other Uroplasty equity awards, awards based on Vision Shares, in each case, on terms substantially identical to those in effect
prior to the Merger Effective Time, except for the adjustments to the underlying number of shares and the exercise price based
on the exchange ratio used in the Merger and other adjustments as provided in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description
of the Merger Agreement is not complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which
was filed as Exhibit 2.1 to the Form 8-K filed by Vision on December 22, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vision registered the
issuance of the Vision Shares to the shareholders of Uroplasty with the Securities and Exchange Commission on a Registration Statement
on Form S-4 (File No. 333-201721).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>Item 3.03.&#9;Material Modification
to Rights of Security Holders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As reported in Item
5.03 and 5.07 below, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Certificate
of Incorporation and the Company amended its Amended and Restated Certificate of Incorporation to effectuate a one-for-five reverse
stock split. The information contained in Item 5.03 and 5.07 of this Current Report on Form 8-K pertaining to this reverse stock
split is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 4.01. &#9;Changes in Registrant&#8217;s Certifying Accountant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2015,
as a result of the completion of the Merger, which constituted a &#8220;reverse acquisition&#8221; of Vision by Uroplasty for tax
and accounting purposes, the Audit Committee of the Company&#8217;s Board of Directors changed the independent registered public
accounting firm from EisnerAmper LLP (&#8220;<U>EisnerAmper</U>&#8221;) to Grant Thornton LLP (&#8220;<U>Grant Thornton</U>&#8221;)
for the year ending March 31, 2015, both with immediate effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">EisnerAmper&#8217;s
report on the Company&#8217;s financial statements for each of the past two fiscal years ended March 31, 2014 and 2013 did not
contain an adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting
principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal years
ended March 31, 2014 and 2013 and the subsequent interim period, there were no: (i) disagreements with EisnerAmper on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope of procedure which, if not resolved to
the satisfaction of EisnerAmper, would have caused EisnerAmper to make reference to the matter in their report, or (ii) reportable
events as defined in Item 304(a)(1)(v) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal years
ended March 31, 2014 and 2013 and the subsequent interim period, neither the Company nor anyone acting on its behalf consulted
Grant Thornton regarding either: (i) the application of accounting principles to a specific transaction, either completed or proposed,
or the type of audit opinion that might be rendered on the Company&#8217;s financial statements, and either a written report was
provided to the Company or oral advice was provided that Grant Thornton concluded was an important factor considered by the Company
in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject
of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable event (as described in Item 304(a)(1)(v)
of Regulation S-K).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has provided
the disclosure in this Item to EisnerAmper, and, as required by Item 304 of Regulation S-K, is filing as Exhibit 16.1 hereto the
letter received from EisnerAmper in response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>Item 5.01.&#9;Change in Control
of Registrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set
forth under Items 2.01 and 5.02 is hereby incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described in Items
2.01, pursuant to the Merger Agreement, on March 31, 2015, Uroplasty merged with and into Merger Sub, with Merger Sub surviving
as a wholly owned subsidiary of the Company. As of the Merger Effective Time, each Uroplasty Share then issued and outstanding
(other than Uroplasty Shares held by Uroplasty as treasury stock and Uroplasty Shares owned by Uroplasty, the Company or any of
their respective subsidiaries) ceased to be issued and outstanding and was automatically converted into the right to receive the
Merger Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the
Merger, a change in control of Vision occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description
of the Merger Agreement is qualified in its entirety by reference to the Merger Agreement, a copy of which was filed as Exhibit
2.1 to the Form 8-K filed by the Company on December 22, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>Item 5.02.&#9;Departures of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the completion of the Merger and in accordance with the terms of the Merger Agreement, the Board of Directors of the Company accepted
the resignations, dated March 30, 2015, of the following directors of the Company with such resignations effective as of the Merger
Effective Time: David W. Anderson; Katsumi Oneda; and John Rydzewski.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
of the Company also accepted the resignation, dated March 30, 2015, of Howard I. Zauberman, as President and Chief Executive Officer
of the Company, with his resignation effective as of the Merger Effective Time. Mr. Zauberman will remain a director of the Company
following the effectiveness of the Merger. The Board of Directors of the Company also determined that the following executive officers
will no longer serve as executive officers of the Company effective as of the Merger Effective Time, but will remain employees
of the Company: Mark Landman, Vice President, Disposables Operations; Jitendra Patel, Vice President, Industrial Division; and
Gary Siegel, Vice President, Finance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
of the Company further fixed the number of directors at eight, and elected the following five individuals to serve as directors,
effective at completion of the Merger and until the Company&#8217;s annual meeting of stockholders where their term expires, until
their respective successors are elected and qualified or until their earlier resignation or removal:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Class III Directors:
Term Ending at 2015 Annual Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Kevin H.
Roche and Kenneth H. Paulus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Class I Directors:
Term Ending at 2016 Annual Meeting </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">James P.
Stauner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Class II Directors:
Term Ending at 2017 Annual Meeting </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Robert C.
Kill and Sven A. Wehrwein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of the
Board of Directors of the Company now consists of the following individuals serving in the following classes with the following
terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1pt solid; padding-top: 0.75pt; padding-right: 6pt; padding-bottom: 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class III Directors:</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Term Ending at 2015</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Annual Meeting</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding: 0.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 34%; border-bottom: Black 1pt solid; padding: 0.75pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class I Directors:</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Term Ending at 2016</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Annual Meeting</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding: 0.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1pt solid; padding: 0.75pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class II Directors:</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Term Ending at 2017</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Annual Meeting</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.75pt; padding-right: 6pt; padding-bottom: 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt">Kevin H. Roche</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Lewis C. Pell</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Robert C. Kill</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.75pt; padding-right: 6pt; padding-bottom: 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt">Kenneth H. Paulus</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">James P. Stauner</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Sven A. Wehrwein</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.75pt; padding-right: 6pt; padding-bottom: 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Howard I. Zauberman</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Dr. Cheryl Pegus</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, Mr. Kill was
appointed Chair of the Board of Directors of the Company, and Mr. Stauner was appointed as Lead Director by the Board of Directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committees of the
Board of Directors of the Company were reconstituted as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Audit Committee: Kevin H. Roche, James P. Stauner; and Sven A. Wehrwein (chair of the committee)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Compensation Committee: Kenneth H. Paulus (chair of the committee); Dr. Cheryl Pegus; and Sven
A. Wehrwein</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Governance and Nominating Committee: Kenneth H. Paulus; Dr. Cheryl Pegus; and Kevin H. Roche (chair
of the committee)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by Item 5.02(d)(5) for the members of the Board of Directors is set forth in the Company&#8217;s Registration Statement on Form
S-4 (File No. 333-201721) and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
also appointed the following individuals to serve as executive officers of the Company effective at the Merger Effective Time and
until their respective successors are elected and qualified or until their earlier resignation or removal:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Name</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 68%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Office(s)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Robert C. Kill</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Darin Hammers</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Senior Vice President, Global Sales and Marketing</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Brett A. Reynolds</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Senior Vice President, Chief Financial Officer and Corporate Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by Items 5.02(c)(2) and (3) of Form 8-K for the above mentioned executive officers is set forth in the Company&#8217;s Registration
Statement on Form S-4 (File No. 333-201721) and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>Item 5.03.&#9;Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger
Agreement, effective upon the Merger Effective Time, the Company&#8217;s Amended and Restated Certificate of Incorporation was
amended to change the name of the Company from &#8220;Vision-Sciences, Inc.&#8221; to &#8220;Cogentix Medical, Inc.&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, effective
immediately prior to the Merger Effective Time, the Company&#8217;s Amended and Restated Certificate of Incorporation was amended
to effect a one-for-five reverse split of Vision&#8217;s common stock (the &#8220;<U>Reverse Stock Split</U>&#8221;). The Certificate
of Amendment provides that the Reverse Stock Split became effective at 4:05 p.m., Eastern time, on March 31, 2015 (the &#8220;<U>Split
Effective Time</U>&#8221;), at which time every five issued and outstanding Vision Shares were automatically combined into one
issued and outstanding Vision Share, without any change in the par value per share. The Certificate of Amendment provides that
in lieu of any fractional share of Vision common stock to which a stockholder otherwise would be entitled as a result of the Reverse
Stock Split, the Company will pay a cash amount equal to the fair value of the fractional share of common stock as of the Split
Effective Time which shall be equal to a proportional interest of the value of a whole share based on the closing sale price of
the Vision common stock on NASDAQ on March 31, 2015, as adjusted for the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the completion
of the Merger and the Reverse Stock Split, the Company had approximately 25.75 million shares of Common Stock issued and outstanding.
All outstanding options, convertible promissory notes, warrants or other awards to purchase Vision Shares will be adjusted proportionately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Trading of the Company&#8217;s
common stock will continue on NASDAQ on a split-adjusted basis on April 1, 2015 under the new symbol &#8220;CGNT&#8221;. The new
CUSIP number for the Company&#8217;s common stock following the Reverse Stock Split is 19243A 104.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description
of the amendments to the Company&#8217;s Amended and Restated Certificate of Incorporation are qualified in its entirety by reference
to Exhibits 3.1 and 3.2 hereto, which are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>Item 5.07.&#9;Submission
of Matters to a Vote of Security Holders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 30, 2015,
Vision held a Special Meeting of Stockholders at its corporate offices in Orangeburg, New York (the &#8220;<U>Special Meeting</U>&#8221;).
At the Special Meeting, the following proposals were submitted to a vote by stockholders, the results for each of which are set
forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&#9;To approve (a) the agreement and
plan of merger, dated as of December 21, 2014, among the Company, Uroplasty, and Merger Sub, which provides, among other things,
for the merger of Uroplasty, Inc. with and into Visor Merger Sub LLC and the conversion of each share of Uroplasty common stock
outstanding immediately prior to the merger into the right to receive 3.6331 shares of common stock of Vision, and (b) the issuance
of shares of Vision&#8217;s common stock in connection with the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 24%; border-top: Black 3pt double; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 28%; border-top: Black 3pt double; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 26%; border-top: Black 3pt double; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 22%; border-top: Black 3pt double; border-right: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>FOR</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>AGAINST</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>ABSTAIN</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BROKER</B>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-VOTE</B>&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">29,004,124</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">320,240</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">76,471</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">0</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&#9;To approve, on an advisory basis,
specified compensatory arrangements between Vision and its named executive officers relating to the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 24%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 28%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 26%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 22%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>FOR</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>AGAINST</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>ABSTAIN</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BROKER</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-VOTE</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">28,212,913</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">1,073,014</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">114,908</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">0</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&#9;To approve an amendment to Vision&#8217;s
Amended and Restated Certificate of Incorporation to change the name of the company from &#8220;Vision-Sciences, Inc.&#8221; to
&#8220;Cogentix Medical, Inc.&#8221; effective as of the effective time of the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border: black 1pt solid; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 24%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 28%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 26%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 22%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>FOR</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>AGAINST</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>ABSTAIN</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BROKER</B>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-VOTE</B>&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">29,075,274</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">308,890</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">16,671</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">0</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&#9;To approve an amendment to Vision&#8217;s
Amended and Restated Certificate of Incorporation to effect a reverse split of Vision&#8217;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border: black 1pt solid; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 24%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 28%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 26%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 22%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>FOR</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>AGAINST</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>ABSTAIN</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BROKER</B>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-VOTE</B>&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">28,988,494</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">363,340</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">49,001</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">0</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&#9;To approve an amendment to Vision&#8217;s
Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000
to 275,000,000 effective as of the effective time of the merger, if the proposal to effect the reverse stock split is not approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border: black 1pt solid; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 24%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 28%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 26%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 22%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>FOR</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>AGAINST</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>ABSTAIN</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BROKER</B>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-VOTE</B>&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center">28,907,897</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">366,081</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">126,857</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">0</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&#9;To approve the Cogentix Medical,
Inc. 2015 Omnibus Incentive Plan effective as of the effective time of the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border: black 1pt solid">
<TR>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 24%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 28%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 26%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 22%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>FOR</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>AGAINST</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>ABSTAIN</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BROKER</B>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-VOTE</B>&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center">28,924,131</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center">398,168</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center">78,536</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center">0</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&#9;To approve amendments to all of the
convertible promissory notes and warrants held by Lewis C. Pell, the Chairman of the Vision board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border: black 1pt solid">
<TR>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 24%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 28%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 26%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 22%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>FOR</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>AGAINST</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>ABSTAIN</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BROKER</B>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-VOTE</B>&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center">28,939,238</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center">345,341</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center">116,256</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center">0</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&#9;To approve any motion to adjourn
the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of the foregoing
proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border: black 1pt solid">
<TR>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 24%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 28%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-left: Black 1pt solid; width: 26%">&nbsp;</TD>
    <TD STYLE="border-top: Black 3pt double; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 22%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>FOR</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>AGAINST</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>ABSTAIN</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BROKER</B>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-VOTE</B>&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center">28,868,486</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center">440,228</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center">92,121</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center">0</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>Item 7.01.&#9;Regulation
FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 30, 2015,
Uroplasty and Vision issued a joint press release announcing that its shareholders had approved the Merger Agreement and the transactions
set forth in the Merger Agreement, a copy of which is included as Exhibit 99.1 to this report and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31,
2015, Vision issued a press release announcing the one-for-five reverse stock split, a copy of which is included as
Exhibit 99.2 to this report and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2015,
Uroplasty and Vision issued a joint press release announcing the completion of the Merger and the transactions set forth in the
Merger Agreement. A copy of the press release is included as Exhibit 99.3 to this report and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in
this Item 7.01 (including the press release) is furnished and shall not be deemed to be &#8220;filed&#8221; for the purposes of
Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01&#9;Financial Statements and
Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#9;<I>Financial
statements of businesses acquired.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by Item 9.01(a) of this report is set forth in the Company&#8217;s Registration Statement on Form S-4 (File No. 333-201721) and
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#9;<I>Pro forma
financial information.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by Item 9.01(b) of this report is set forth in the Company&#8217;s Registration Statement on Form S-4 (File No. 333-201721) and
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&#9;<I>Exhibits</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Exhibit
No.</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 80%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Description</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement and Plan of Merger, dated as
        of December 21, 2014, among Vision-Sciences, Inc., Visor Merger Sub LLC and Uroplasty, Inc. (Incorporated by reference to Exhibit
        2.1 to the Company&#8217;s current report on Form 8-K filed on December 22, 2014).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amendment to the Registrant&#8217;s Amended
        and Restated Certificate of Incorporation to Change the Registrant&#8217;s Name dated March 31, 2015 (Filed herewith).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amendment to the Registrant&#8217;s Amended
        and Restated Certificate of Incorporation to effect the Reverse Stock Split dated March 31, 2015 (Filed herewith).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Letter from EisnerAmper LLP regarding change
        in certifying accountants (Filed herewith).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consent of Grant Thornton LLP (Filed herewith).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Press Release of Uroplasty, Inc. and Vision-Sciences,
        Inc. dated March 30, 2015 (Furnished herewith).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; text-indent: 0in">99.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Press Release of Vision-Sciences, Inc. dated March 31, 2015 (Furnished herewith).</P>
                                                          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">99.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Press Release of Uroplasty, Inc. and Cogentix
        Medical, Inc. (f/k/a Vision-Sciences, Inc.) dated March 31, 2015 (Furnished herewith).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Dated: March 31, 2015</TD>
    <TD COLSPAN="2"><B>COGENTIX MEDICAL, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 53%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Brett Reynolds</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Brett Reynolds</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Senior Vice President,
Chief Financial Officer and Corporate Secretary</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COGENTIX MEDICAL, INC.</B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">CURRENT
REPORT ON FORM 8-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">EXHIBIT
INDEX</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit No.</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 56%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Method of Filing</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Agreement and Plan of Merger, dated as of December 21, 2014, among Vision-Sciences, Inc., Visor Merger Sub LLC and Uroplasty, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incorporated by reference to Exhibit 2.1 to the Company&#8217;s
        current report on Form 8-K filed on December 22, 2014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amendment to the Registrant&#8217;s Amended and Restated Certificate
        of Incorporation dated March 31, 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Filed herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amendment to the Registrant&#8217;s Amended and Restated Certificate
        of Incorporation dated March 31, 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Filed herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">16.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Letter from EisnerAmper LLP regarding change in certifying accountants.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Filed herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consent of Grant Thornton LLP dated March 31, 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Filed herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Press Release of Uroplasty, Inc. and Vision-Sciences, Inc. dated
        March 30, 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Furnished herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">99.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Press Release of Vision-Sciences, Inc. dated March 31, 2015.</P>
                                                          <P>&nbsp;</P>

</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Furnished herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Press Release of Uroplasty, Inc. and Cogentix Medical, Inc.
        (f/k/a Vision-Sciences, Inc.) dated March 31, 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Furnished herewith</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "s000823x2_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 89348}]
{"company-data": {"conformed-name": "COGENTIX MEDICAL INC /DE/", "cik": "0000894237", "assigned-sic": "3845", "irs-number": "133430173", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-20970", "film-number": "15739475"}, "business-address": {"street1": "5420 FELTL ROAD", "city": "MINNETONKA", "state": "MN", "zip": "55343", "phone": "952-426-6140"}, "mail-address": {"street1": "5420 FELTL ROAD", "city": "MINNETONKA", "state": "MN", "zip": "55343"}, "former-company": {"former-conformed-name": "VISION SCIENCES INC /DE/", "date-changed": "19960404"}}
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported):
March 30, 2015
COGENTIX
MEDICAL, INC.
(Exact name of registrant as specified in
its charter)
Delaware
000-20970
13-3430173
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification
No.)
5420 Feltl Road
Minnetonka, Minnesota
55343
(Address of principal executive offices)
(Zip Code)
(952) 426-6140
(Registrant's
telephone number, including area code)
Vision-Sciences, Inc.
40 Ramland Road South
Orangeburg, New York 10962
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.01.	Completion of Acquisition
or Disposition of Assets.
On December 21, 2014,
Vision-Sciences, Inc., a Delaware corporation ("
Vision
" or the "
Company
"), and Visor Merger
Sub LLC, a Delaware limited liability company and of which the sole member is Vision ("
Merger Sub
"), entered
into an Agreement and Plan of Merger (the "
Merger Agreement
") with Uroplasty, Inc., a Minnesota corporation
("
Uroplasty
"), providing for the merger of Uroplasty with and into Merger Sub, with Merger Sub surviving as
a wholly owned subsidiary of Vision (the "
Merger
").
On March 30, 2015,
Vision held a Special Meeting of Shareholders (the "
Special Meeting
") at its corporate headquarters located
in Orangeburg, New York. At the Special Meeting, holders of a majority of the Vision shares entitled to vote at the meeting approved,
among other things, the adoption of the Merger Agreement and the issuance of shares of common stock, $0.01 par value, of Vision
("
Vision Shares
"), in connection with the Merger.
Pursuant to the Merger
Agreement, on March 31, 2015, Uroplasty merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation
under the name "Uroplasty, LLC". Vision changed its name to "Cogentix Medical, Inc." and the Vision Shares
will now trade on the Nasdaq Stock Market ("
NASDAQ
") under the new symbol "CGNT". Following the
completion of the Merger, Uroplasty's common stock, par value $0.01 per share ("
Uroplasty Shares
"), ceased
trading on NASDAQ.
Pursuant to the Merger
Agreement and as of the effective time of the Merger (the "
Merger Effective Time
"), each Uroplasty Share outstanding
immediately prior to the Merger Effective Time (other than Uroplasty Shares held by Uroplasty as treasury stock and Uroplasty
Shares owned by Uroplasty, Vision or any of their respective subsidiaries, which Uroplasty Shares were cancelled) was converted
into the right to receive 0.72662 Vision Shares. This calculation reflected the 3.6331 Exchange Ratio as defined in the Merger
Agreement as adjusted for Vision's one-for-five reverse stock split plus cash (without interest) in lieu of fractional shares,
if any, in an amount equal to the product of (a) such fractional part of a Vision Share, multiplied by (b) $1.85, the closing price
for a Vision Share as reported on NASDAQ on March 30, 2015, the trading day immediately prior to the Merger Effective Time, adjusted for Vision's one-for-five reverse stock split (collectively,
the "
Merger Consideration
").
Immediately following
the Merger Effective Time, Vision shareholders owned approximately 37.5% and Uroplasty shareholders owned approximately 62.5% of
the combined company on a fully-diluted basis, excluding shares of Vision common stock issuable upon the conversion of promissory
notes and warrants held by Mr. Lewis C. Pell, former Chairman of Vision (which were amended in connection with the Merger).
As of the Merger Effective
Time, all outstanding options to purchase Uroplasty Shares and other equity awards based on Uroplasty Shares, which were outstanding
immediately prior to the Merger Effective Time, became, respectively, options to purchase Vision Shares and, with respect to all
other Uroplasty equity awards, awards based on Vision Shares, in each case, on terms substantially identical to those in effect
prior to the Merger Effective Time, except for the adjustments to the underlying number of shares and the exercise price based
on the exchange ratio used in the Merger and other adjustments as provided in the Merger Agreement.
The foregoing description
of the Merger Agreement is not complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which
was filed as Exhibit 2.1 to the Form 8-K filed by Vision on December 22, 2014.
1
Vision registered the
issuance of the Vision Shares to the shareholders of Uroplasty with the Securities and Exchange Commission on a Registration Statement
on Form S-4 (File No. 333-201721).
Item 3.03.	Material Modification
to Rights of Security Holders.
As reported in Item
5.03 and 5.07 below, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate
of Incorporation and the Company amended its Amended and Restated Certificate of Incorporation to effectuate a one-for-five reverse
stock split. The information contained in Item 5.03 and 5.07 of this Current Report on Form 8-K pertaining to this reverse stock
split is incorporated herein by reference.
Item 4.01. 	Changes in Registrant's Certifying Accountant.
On March 31, 2015,
as a result of the completion of the Merger, which constituted a "reverse acquisition" of Vision by Uroplasty for tax
and accounting purposes, the Audit Committee of the Company's Board of Directors changed the independent registered public
accounting firm from EisnerAmper LLP ("
EisnerAmper
") to Grant Thornton LLP ("
Grant Thornton
")
for the year ending March 31, 2015, both with immediate effect.
EisnerAmper's
report on the Company's financial statements for each of the past two fiscal years ended March 31, 2014 and 2013 did not
contain an adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting
principles.
During the fiscal years
ended March 31, 2014 and 2013 and the subsequent interim period, there were no: (i) disagreements with EisnerAmper on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope of procedure which, if not resolved to
the satisfaction of EisnerAmper, would have caused EisnerAmper to make reference to the matter in their report, or (ii) reportable
events as defined in Item 304(a)(1)(v) of Regulation S-K.
During the fiscal years
ended March 31, 2014 and 2013 and the subsequent interim period, neither the Company nor anyone acting on its behalf consulted
Grant Thornton regarding either: (i) the application of accounting principles to a specific transaction, either completed or proposed,
or the type of audit opinion that might be rendered on the Company's financial statements, and either a written report was
provided to the Company or oral advice was provided that Grant Thornton concluded was an important factor considered by the Company
in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject
of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable event (as described in Item 304(a)(1)(v)
of Regulation S-K).
The Company has provided
the disclosure in this Item to EisnerAmper, and, as required by Item 304 of Regulation S-K, is filing as Exhibit 16.1 hereto the
letter received from EisnerAmper in response.
Item 5.01.	Change in Control
of Registrant.
The information set
forth under Items 2.01 and 5.02 is hereby incorporated by reference herein.
As described in Items
2.01, pursuant to the Merger Agreement, on March 31, 2015, Uroplasty merged with and into Merger Sub, with Merger Sub surviving
as a wholly owned subsidiary of the Company. As of the Merger Effective Time, each Uroplasty Share then issued and outstanding
(other than Uroplasty Shares held by Uroplasty as treasury stock and Uroplasty Shares owned by Uroplasty, the Company or any of
their respective subsidiaries) ceased to be issued and outstanding and was automatically converted into the right to receive the
Merger Consideration.
2
As a result of the
Merger, a change in control of Vision occurred.
The foregoing description
of the Merger Agreement is qualified in its entirety by reference to the Merger Agreement, a copy of which was filed as Exhibit
2.1 to the Form 8-K filed by the Company on December 22, 2014.
Item 5.02.	Departures of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
In connection with
the completion of the Merger and in accordance with the terms of the Merger Agreement, the Board of Directors of the Company accepted
the resignations, dated March 30, 2015, of the following directors of the Company with such resignations effective as of the Merger
Effective Time: David W. Anderson; Katsumi Oneda; and John Rydzewski.
The Board of Directors
of the Company also accepted the resignation, dated March 30, 2015, of Howard I. Zauberman, as President and Chief Executive Officer
of the Company, with his resignation effective as of the Merger Effective Time. Mr. Zauberman will remain a director of the Company
following the effectiveness of the Merger. The Board of Directors of the Company also determined that the following executive officers
will no longer serve as executive officers of the Company effective as of the Merger Effective Time, but will remain employees
of the Company: Mark Landman, Vice President, Disposables Operations; Jitendra Patel, Vice President, Industrial Division; and
Gary Siegel, Vice President, Finance.
The Board of Directors
of the Company further fixed the number of directors at eight, and elected the following five individuals to serve as directors,
effective at completion of the Merger and until the Company's annual meeting of stockholders where their term expires, until
their respective successors are elected and qualified or until their earlier resignation or removal:
Class III Directors:
Term Ending at 2015 Annual Meeting
Kevin H.
Roche and Kenneth H. Paulus
Class I Directors:
Term Ending at 2016 Annual Meeting
James P.
Stauner
Class II Directors:
Term Ending at 2017 Annual Meeting
Robert C.
Kill and Sven A. Wehrwein
3
The members of the
Board of Directors of the Company now consists of the following individuals serving in the following classes with the following
terms:
Class III Directors:
Term Ending at 2015
Annual Meeting
Class I Directors:
Term Ending at 2016
Annual Meeting
Class II Directors:
Term Ending at 2017
Annual Meeting
Kevin H. Roche
Lewis C. Pell
Robert C. Kill
Kenneth H. Paulus
James P. Stauner
Sven A. Wehrwein
Howard I. Zauberman
Dr. Cheryl Pegus
Further, Mr. Kill was
appointed Chair of the Board of Directors of the Company, and Mr. Stauner was appointed as Lead Director by the Board of Directors
of the Company.
The Committees of the
Board of Directors of the Company were reconstituted as follows:
·
Audit Committee: Kevin H. Roche, James P. Stauner; and Sven A. Wehrwein (chair of the committee)
·
Compensation Committee: Kenneth H. Paulus (chair of the committee); Dr. Cheryl Pegus; and Sven
A. Wehrwein
·
Governance and Nominating Committee: Kenneth H. Paulus; Dr. Cheryl Pegus; and Kevin H. Roche (chair
of the committee)
The information required
by Item 5.02(d)(5) for the members of the Board of Directors is set forth in the Company's Registration Statement on Form
S-4 (File No. 333-201721) and is incorporated herein by reference.
The Board of Directors
also appointed the following individuals to serve as executive officers of the Company effective at the Merger Effective Time and
until their respective successors are elected and qualified or until their earlier resignation or removal:
Name
Office(s)
Robert C. Kill
President and Chief Executive Officer
Darin Hammers
Senior Vice President, Global Sales and Marketing
Brett A. Reynolds
Senior Vice President, Chief Financial Officer and Corporate Secretary
The information required
by Items 5.02(c)(2) and (3) of Form 8-K for the above mentioned executive officers is set forth in the Company's Registration
Statement on Form S-4 (File No. 333-201721) and is incorporated herein by reference.
4
Item 5.03.	Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Pursuant to the Merger
Agreement, effective upon the Merger Effective Time, the Company's Amended and Restated Certificate of Incorporation was
amended to change the name of the Company from "Vision-Sciences, Inc." to "Cogentix Medical, Inc.".
Further, effective
immediately prior to the Merger Effective Time, the Company's Amended and Restated Certificate of Incorporation was amended
to effect a one-for-five reverse split of Vision's common stock (the "
Reverse Stock Split
"). The Certificate
of Amendment provides that the Reverse Stock Split became effective at 4:05 p.m., Eastern time, on March 31, 2015 (the "
Split
Effective Time
"), at which time every five issued and outstanding Vision Shares were automatically combined into one
issued and outstanding Vision Share, without any change in the par value per share. The Certificate of Amendment provides that
in lieu of any fractional share of Vision common stock to which a stockholder otherwise would be entitled as a result of the Reverse
Stock Split, the Company will pay a cash amount equal to the fair value of the fractional share of common stock as of the Split
Effective Time which shall be equal to a proportional interest of the value of a whole share based on the closing sale price of
the Vision common stock on NASDAQ on March 31, 2015, as adjusted for the Reverse Stock Split.
Following the completion
of the Merger and the Reverse Stock Split, the Company had approximately 25.75 million shares of Common Stock issued and outstanding.
All outstanding options, convertible promissory notes, warrants or other awards to purchase Vision Shares will be adjusted proportionately.
Trading of the Company's
common stock will continue on NASDAQ on a split-adjusted basis on April 1, 2015 under the new symbol "CGNT". The new
CUSIP number for the Company's common stock following the Reverse Stock Split is 19243A 104.
The foregoing description
of the amendments to the Company's Amended and Restated Certificate of Incorporation are qualified in its entirety by reference
to Exhibits 3.1 and 3.2 hereto, which are incorporated herein by reference.
Item 5.07.	Submission
of Matters to a Vote of Security Holders.
On March 30, 2015,
Vision held a Special Meeting of Stockholders at its corporate offices in Orangeburg, New York (the "
Special Meeting
").
At the Special Meeting, the following proposals were submitted to a vote by stockholders, the results for each of which are set
forth below:
1.	To approve (a) the agreement and
plan of merger, dated as of December 21, 2014, among the Company, Uroplasty, and Merger Sub, which provides, among other things,
for the merger of Uroplasty, Inc. with and into Visor Merger Sub LLC and the conversion of each share of Uroplasty common stock
outstanding immediately prior to the merger into the right to receive 3.6331 shares of common stock of Vision, and (b) the issuance
of shares of Vision's common stock in connection with the merger.
FOR
AGAINST
ABSTAIN
BROKER
NON-VOTE
29,004,124
320,240
76,471
0
5
2.	To approve, on an advisory basis,
specified compensatory arrangements between Vision and its named executive officers relating to the merger.
FOR
AGAINST
ABSTAIN
BROKER
NON-VOTE
28,212,913
1,073,014
114,908
0
3.	To approve an amendment to Vision's
Amended and Restated Certificate of Incorporation to change the name of the company from "Vision-Sciences, Inc." to
"Cogentix Medical, Inc." effective as of the effective time of the merger.
FOR
AGAINST
ABSTAIN
BROKER
NON-VOTE
29,075,274
308,890
16,671
0
4.	To approve an amendment to Vision's
Amended and Restated Certificate of Incorporation to effect a reverse split of Vision's common stock.
FOR
AGAINST
ABSTAIN
BROKER
NON-VOTE
28,988,494
363,340
49,001
0
5.	To approve an amendment to Vision's
Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000
to 275,000,000 effective as of the effective time of the merger, if the proposal to effect the reverse stock split is not approved.
FOR
AGAINST
ABSTAIN
BROKER
NON-VOTE
28,907,897
366,081
126,857
0
6.	To approve the Cogentix Medical,
Inc. 2015 Omnibus Incentive Plan effective as of the effective time of the merger.
FOR
AGAINST
ABSTAIN
BROKER
NON-VOTE
28,924,131
398,168
78,536
0
7.	To approve amendments to all of the
convertible promissory notes and warrants held by Lewis C. Pell, the Chairman of the Vision board of directors.
FOR
AGAINST
ABSTAIN
BROKER
NON-VOTE
28,939,238
345,341
116,256
0
8.	To approve any motion to adjourn
the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of the foregoing
proposals.
FOR
AGAINST
ABSTAIN
BROKER
NON-VOTE
28,868,486
440,228
92,121
0
6
Item 7.01.	Regulation
FD Disclosure.
On March 30, 2015,
Uroplasty and Vision issued a joint press release announcing that its shareholders had approved the Merger Agreement and the transactions
set forth in the Merger Agreement, a copy of which is included as Exhibit 99.1 to this report and is incorporated herein by reference.
On March 31,
2015, Vision issued a press release announcing the one-for-five reverse stock split, a copy of which is included as
Exhibit 99.2 to this report and is incorporated herein by reference.
On March 31, 2015,
Uroplasty and Vision issued a joint press release announcing the completion of the Merger and the transactions set forth in the
Merger Agreement. A copy of the press release is included as Exhibit 99.3 to this report and is incorporated herein by reference.
The information in
this Item 7.01 (including the press release) is furnished and shall not be deemed to be "filed" for the purposes of
Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such a filing.
Item 9.01	Financial Statements and
Exhibits.
(a)
Financial
statements of businesses acquired.
The information required
by Item 9.01(a) of this report is set forth in the Company's Registration Statement on Form S-4 (File No. 333-201721) and
is incorporated herein by reference.
(b)
Pro forma
financial information.
The information required
by Item 9.01(b) of this report is set forth in the Company's Registration Statement on Form S-4 (File No. 333-201721) and
is incorporated herein by reference.
(d)
Exhibits
.
Exhibit
No.
Description
2.1
Agreement and Plan of Merger, dated as
        of December 21, 2014, among Vision-Sciences, Inc., Visor Merger Sub LLC and Uroplasty, Inc. (Incorporated by reference to Exhibit
        2.1 to the Company's current report on Form 8-K filed on December 22, 2014).
3.1
Amendment to the Registrant's Amended
        and Restated Certificate of Incorporation to Change the Registrant's Name dated March 31, 2015 (Filed herewith).
3.2
Amendment to the Registrant's Amended
        and Restated Certificate of Incorporation to effect the Reverse Stock Split dated March 31, 2015 (Filed herewith).
16.1
Letter from EisnerAmper LLP regarding change
        in certifying accountants (Filed herewith).
23.1
Consent of Grant Thornton LLP (Filed herewith).
99.1
Press Release of Uroplasty, Inc. and Vision-Sciences,
        Inc. dated March 30, 2015 (Furnished herewith).
99.2
Press Release of Vision-Sciences, Inc. dated March 31, 2015 (Furnished herewith).
99.3
Press Release of Uroplasty, Inc. and Cogentix
        Medical, Inc. (f/k/a Vision-Sciences, Inc.) dated March 31, 2015 (Furnished herewith).
7
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: March 31, 2015
COGENTIX MEDICAL, INC.
By:
/s/ Brett Reynolds
Name:
Brett Reynolds
Title:
Senior Vice President,
Chief Financial Officer and Corporate Secretary
8
COGENTIX MEDICAL, INC.
CURRENT
REPORT ON FORM 8-K
EXHIBIT
INDEX
Exhibit No.
Description
Method of Filing
2.1
Agreement and Plan of Merger, dated as of December 21, 2014, among Vision-Sciences, Inc., Visor Merger Sub LLC and Uroplasty, Inc.
Incorporated by reference to Exhibit 2.1 to the Company's
        current report on Form 8-K filed on December 22, 2014
3.1
Amendment to the Registrant's Amended and Restated Certificate
        of Incorporation dated March 31, 2015.
Filed herewith
3.2
Amendment to the Registrant's Amended and Restated Certificate
        of Incorporation dated March 31, 2015.
Filed herewith
16.1
Letter from EisnerAmper LLP regarding change in certifying accountants.
Filed herewith
23.1
Consent of Grant Thornton LLP dated March 31, 2015.
Filed herewith
99.1
Press Release of Uroplasty, Inc. and Vision-Sciences, Inc. dated
        March 30, 2015.
Furnished herewith
99.2
Press Release of Vision-Sciences, Inc. dated March 31, 2015.
Furnished herewith
99.2
Press Release of Uroplasty, Inc. and Cogentix Medical, Inc.
        (f/k/a Vision-Sciences, Inc.) dated March 31, 2015.
Furnished herewith
9